Free Trial

Health Catalyst, Inc. (NASDAQ:HCAT) Short Interest Update

Health Catalyst logo with Medical background

Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) was the target of a significant increase in short interest in October. As of October 31st, there was short interest totalling 2,840,000 shares, an increase of 8.8% from the October 15th total of 2,610,000 shares. Based on an average daily volume of 473,600 shares, the days-to-cover ratio is currently 6.0 days.

Wall Street Analyst Weigh In

Several brokerages have commented on HCAT. JPMorgan Chase & Co. boosted their price target on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 4th. Royal Bank of Canada lifted their price target on Health Catalyst from $8.00 to $9.00 and gave the stock a "sector perform" rating in a research note on Thursday, November 7th. Citigroup lifted their price target on Health Catalyst from $9.00 to $10.50 and gave the stock a "buy" rating in a research note on Wednesday. Evercore ISI lifted their price target on Health Catalyst from $8.00 to $10.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 8th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $16.00 price target on shares of Health Catalyst in a research note on Friday, October 4th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat, Health Catalyst currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.71.

Check Out Our Latest Report on Health Catalyst

Health Catalyst Stock Down 9.5 %

NASDAQ:HCAT traded down $0.80 on Friday, hitting $7.65. 735,511 shares of the company's stock traded hands, compared to its average volume of 548,477. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst has a 1 year low of $5.42 and a 1 year high of $11.41. The firm has a 50-day moving average price of $8.16 and a 200-day moving average price of $7.23. The company has a market cap of $465.50 million, a PE ratio of -5.67 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The business had revenue of $76.40 million for the quarter, compared to analysts' expectations of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company's revenue was up 3.5% compared to the same quarter last year. During the same period last year, the firm earned ($0.22) EPS. Equities analysts anticipate that Health Catalyst will post -0.35 EPS for the current fiscal year.

Insider Activity at Health Catalyst

In other Health Catalyst news, insider Kevin Lee Freeman sold 7,500 shares of the business's stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the sale, the insider now directly owns 255,881 shares in the company, valued at approximately $1,847,460.82. The trade was a 2.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Daniel Lesueur sold 5,209 shares of the business's stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total transaction of $40,005.12. Following the completion of the sale, the chief operating officer now owns 134,899 shares in the company, valued at approximately $1,036,024.32. This trade represents a 3.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 34,068 shares of company stock worth $257,555 over the last ninety days. 2.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Health Catalyst

Several large investors have recently made changes to their positions in HCAT. Quest Partners LLC acquired a new stake in Health Catalyst in the 3rd quarter worth approximately $34,000. Nisa Investment Advisors LLC lifted its holdings in Health Catalyst by 461.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company's stock worth $41,000 after purchasing an additional 5,232 shares during the last quarter. Quarry LP lifted its holdings in Health Catalyst by 59.4% in the 2nd quarter. Quarry LP now owns 7,002 shares of the company's stock worth $45,000 after purchasing an additional 2,610 shares during the last quarter. nVerses Capital LLC acquired a new stake in Health Catalyst in the 3rd quarter worth approximately $59,000. Finally, Perfromance Wealth Partners LLC acquired a new stake in Health Catalyst in the 2nd quarter worth approximately $64,000. Institutional investors own 85.00% of the company's stock.

About Health Catalyst

(Get Free Report)

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should you invest $1,000 in Health Catalyst right now?

Before you consider Health Catalyst, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Health Catalyst wasn't on the list.

While Health Catalyst currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

’Best Report in 2 Years’: NVIDIA Earnings Crushes Expectations Again
Palantir and the NASDAQ 100: What’s the Next Big Stock Swing for This AI Giant?
Rocket Lab Stock Explodes Higher—What’s Next for This Space Pioneer?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines